Introduktion
Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for Ted W Love. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.
Gennemsnitlig handelsrentabilitet
Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.
Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.
Opdateringsfrekvens: Dagligt
Virksomheder med rapporterede insider-stillinger
SEC-registreringen viser, at Ted W Love har rapporteret besiddelser eller handler i følgende virksomheder:
Sikkerhed | Titel | Senest indberettede beholdninger |
---|---|---|
US:RPRX / Royalty Pharma plc | Director | 53.848 |
US:GILD / Gilead Sciences, Inc. | Director | 4.338 |
US:SGEN / Seagen Inc | Director | 0 |
US:GBT / Global Blood Therapeutics Inc. | President and CEO, Director | 0 |
Director | 0 | |
US:FOLD / Amicus Therapeutics, Inc. | Director | 18.574 |
US:CASC / Cascadian Therapeutics, Inc. | Director | 0 |
US:KBIO / KaloBios Pharmaceuticals, Inc. | Director | 5.000 |
US:SNTS / Santarus, Inc | Director | 0 |
US:MSTX / Tidal Trust II - Defiance Daily Target 2X Long MSTR ETF | Director | 62.451 |
US:ONXX / Onyx Pharmaceuticals Inc | EVP, R&D and Tech. Operations | 77.756 |
US:AFFY / Affymax, Inc. | Director | 12.000 |
US:ABIO / ARCA biopharma, Inc. | Director | 7.500 |
Sådan fortolkes diagrammerne
Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af Ted W Love. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.
I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.
Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.
Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.
Insiderkøb AFFY / Affymax, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AFFY / Affymax, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg AFFY / Affymax, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AFFY / Affymax, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb FOLD / Amicus Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AFFY / Affymax, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg FOLD / Amicus Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AFFY / Affymax, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb MSTX / Tidal Trust II - Defiance Daily Target 2X Long MSTR ETF – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AFFY / Affymax, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg MSTX / Tidal Trust II - Defiance Daily Target 2X Long MSTR ETF – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AFFY / Affymax, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb RPRX / Royalty Pharma plc – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AFFY / Affymax, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg RPRX / Royalty Pharma plc – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AFFY / Affymax, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderhandelshistorie
Denne tabel viser den komplette liste over insiderhandler foretaget af Ted W Love som oplyst til Securities Exchange Commission (SEC).
Fil dato | Transdato | Form | Ticker | Sikkerhed | Kode | Aktier | Resterende aktier | Procent Lave om |
Del Pris |
Tran Værdi |
Tilbage Værdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-05-14 |
|
4 | RPRX |
Royalty Pharma plc
Class A Ordinary Shares |
A - Award | 7.614 | 53.848 | 16,47 | ||||
2025-05-08 |
|
4 | GILD |
GILEAD SCIENCES, INC.
Common Stock |
A - Award | 1.516 | 4.338 | 53,72 | ||||
2024-06-10 |
|
4 | RPRX |
Royalty Pharma plc
Class A Ordinary Shares |
A - Award | 9.293 | 46.234 | 25,16 | ||||
2024-05-09 |
|
4 | GILD |
GILEAD SCIENCES, INC.
Common Stock |
A - Award | 2.310 | 2.822 | 451,17 | ||||
2024-02-06 |
|
4 | GILD |
GILEAD SCIENCES, INC.
Common Stock |
A - Award | 512 | 512 | |||||
2023-12-15 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
D - Sale to Issuer | -4.255 | 0 | -100,00 | 229,00 | -974.395 | ||
2023-06-26 |
|
4 | RPRX |
Royalty Pharma plc
Class A Ordinary Shares |
A - Award | 7.747 | 36.941 | 26,54 | ||||
2023-06-02 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
A - Award | 2.044 | 6.748 | 43,45 | ||||
2022-10-06 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -2.500 | 0 | -100,00 | ||||
2022-10-06 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -2.500 | 0 | -100,00 | ||||
2022-10-06 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -102.000 | 0 | -100,00 | ||||
2022-10-06 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -119.650 | 0 | -100,00 | ||||
2022-10-06 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -119.650 | 0 | -100,00 | ||||
2022-10-06 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -576.318 | 0 | -100,00 | ||||
2022-09-29 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 18.291 | 576.318 | 3,28 | 16,40 | 299.972 | 9.451.615 | |
2022-09-29 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
G - Gift | 17.650 | 119.650 | 17,30 | ||||
2022-09-29 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
G - Gift | 17.650 | 119.650 | 17,30 | ||||
2022-09-29 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
G - Gift | -35.300 | 558.027 | -5,95 | ||||
2022-09-29 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
G - Gift | -221.200 | 593.327 | -27,16 | ||||
2022-09-06 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -9.200 | 814.527 | -1,12 | 68,15 | -626.980 | 55.510.015 | |
2022-09-06 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 9.109 | 823.727 | 1,12 | ||||
2022-09-06 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 9.444 | 814.618 | 1,17 | ||||
2022-08-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -10.018 | 805.174 | -1,23 | 32,40 | -324.583 | 26.087.638 | |
2022-08-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 20.205 | 815.192 | 2,54 | ||||
2022-06-24 |
|
4 | RPRX |
Royalty Pharma plc
Class A Ordinary Shares |
A - Award | 6.328 | 29.194 | 27,67 | ||||
2022-05-17 |
|
4 | SGEN |
Seagen Inc.
Non-Qualified Stock Option (right to buy) |
A - Award | 3.676 | 3.676 | |||||
2022-05-17 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
A - Award | 1.503 | 4.704 | 46,95 | ||||
2022-03-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Stock Option (Right to buy) |
A - Award | 118.090 | 118.090 | |||||
2022-03-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
A - Award | 72.877 | 72.877 | |||||
2022-03-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
A - Award | 72.877 | 72.877 | |||||
2022-03-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -9.445 | 56.667 | -14,29 | ||||
2022-03-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -4.074 | 794.987 | -0,51 | 29,87 | -121.690 | 23.746.262 | |
2022-03-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 9.445 | 799.061 | 1,20 | ||||
2022-03-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
A - Award | 839 | 789.616 | 0,11 | 25,37 | 21.285 | 20.032.558 | |
2022-02-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -8.955 | 35.820 | -20,00 | ||||
2022-02-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -11.250 | 22.500 | -33,33 | ||||
2022-02-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -9.750 | 0 | -100,00 | ||||
2022-02-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -10.531 | 788.777 | -1,32 | 29,33 | -308.874 | 23.134.829 | |
2022-02-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 29.955 | 799.308 | 3,89 | ||||
2022-01-06 |
|
4/A | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -24.821 | 1.117.815 | -2,17 | 3,40 | -84.391 | 3.800.571 | |
2021-09-24 |
|
4/A | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -8.955 | 44.775 | -16,67 | ||||
2021-09-24 |
|
4/A | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -11.250 | 33.750 | -25,00 | ||||
2021-09-24 |
|
4/A | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -9.750 | 9.750 | -50,00 | ||||
2021-09-24 |
|
4/A | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -14.853 | 789.413 | -1,85 | 27,33 | -405.932 | 21.574.657 | |
2021-09-24 |
|
4/A | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 29.955 | 804.266 | 3,87 | ||||
2021-09-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -9.444 | 66.112 | -12,50 | ||||
2021-09-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -4.683 | 794.174 | -0,59 | 29,85 | -139.788 | 23.706.094 | |
2021-09-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 9.444 | 798.857 | 1,20 | ||||
2021-08-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -8.955 | 44.775 | -16,67 | ||||
2021-08-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -11.250 | 33.750 | -25,00 | ||||
2021-08-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -9.750 | 9.750 | -50,00 | ||||
2021-08-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -14.853 | 789.413 | -1,85 | 27,33 | -405.932 | 21.574.657 | |
2021-08-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 29.955 | 804.266 | 3,87 | ||||
2021-06-29 |
|
4 | RPRX |
Royalty Pharma plc
Class A Ordinary Shares |
A - Award | 5.726 | 22.866 | 33,41 | ||||
2021-05-18 |
|
4 | SGEN |
Seagen Inc.
Non-Qualified Stock Option (right to buy) |
A - Award | 3.462 | 3.462 | |||||
2021-05-18 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
A - Award | 1.402 | 3.201 | 77,93 | ||||
2021-03-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
A - Award | 75.556 | 75.556 | |||||
2021-03-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 132.433 | 132.433 | |||||
2021-03-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
A - Award | 370 | 774.311 | 0,05 | 36,21 | 13.398 | 28.037.801 | |
2021-02-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -8.955 | 53.730 | -14,29 | ||||
2021-02-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -11.250 | 45.000 | -20,00 | ||||
2021-02-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -9.750 | 19.500 | -33,33 | ||||
2021-02-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -12.063 | 0 | -100,00 | ||||
2021-02-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -17.893 | 773.941 | -2,26 | 49,49 | -885.525 | 38.302.340 | |
2021-02-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 42.018 | 791.834 | 5,60 | ||||
2020-08-18 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
A - Award | 4.460 | 4.460 | |||||
2020-08-18 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
A - Award | 1.799 | 1.799 | |||||
2020-08-17 |
|
4 | RPRX |
Royalty Pharma plc
Class A Ordinary Shares |
A - Award | 7.280 | 17.280 | 72,80 | ||||
2020-08-10 | 3 | RPRX |
Royalty Pharma plc
Class A Ordinary Shares |
20.000 | ||||||||
2020-08-10 | 3 | RPRX |
Royalty Pharma plc
Class A Ordinary Shares |
20.000 | ||||||||
2020-08-10 | 3 | RPRX |
Royalty Pharma plc
Class A Ordinary Shares |
20.000 | ||||||||
2020-08-04 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -8.955 | 62.685 | -12,50 | ||||
2020-08-04 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -11.250 | 56.250 | -16,67 | ||||
2020-08-04 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -9.750 | 29.250 | -25,00 | ||||
2020-08-04 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -12.062 | 12.063 | -50,00 | ||||
2020-08-04 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -20.834 | 749.816 | -2,70 | 67,48 | -1.405.878 | 50.597.584 | |
2020-08-04 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 42.017 | 770.650 | 5,77 | ||||
2020-08-04 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
G - Gift | -306.000 | 728.633 | -29,58 | ||||
2020-07-02 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -14.812 | 0 | -100,00 | ||||
2020-07-02 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -11.377 | 0 | -100,00 | 0,06 | -683 | ||
2020-07-02 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Restricted Stock Units |
D - Sale to Issuer | -15.575 | 0 | -100,00 | 18,00 | -280.350 | ||
2020-06-15 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 11.377 | 11.377 | |||||
2020-06-15 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Common Stock |
A - Award | 7.281 | 15.575 | 87,79 | ||||
2020-06-08 |
|
4 | FOLD |
AMICUS THERAPEUTICS, INC.
Stock Options (right to buy) |
A - Award | 18.574 | 18.574 | |||||
2020-06-08 |
|
4 | FOLD |
AMICUS THERAPEUTICS, INC.
Common Stock |
A - Award | 5.855 | 131.000 | 4,68 | ||||
2020-06-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
A - Award | 141.400 | 141.400 | |||||
2020-04-29 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -40.000 | 1.034.633 | -3,72 | 80,00 | -3.200.160 | 82.774.779 |
2020-04-29 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -1.517 | 1.074.633 | -0,14 | 80,63 | -122.320 | 86.650.560 |
2020-04-29 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -1.300 | 1.076.150 | -0,12 | 81,15 | -105.494 | 87.328.712 |
2020-02-20 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -1.818 | 1.077.450 | -0,17 | 70,92 | -128.940 | 76.416.956 |
2020-02-20 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -2.189 | 1.079.268 | -0,20 | 70,22 | -153.721 | 75.790.732 |
2020-02-04 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 114.190 | 114.190 | |||||
2020-02-04 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
A - Award | 71.640 | 71.640 | |||||
2020-02-04 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -11.250 | 67.500 | -14,29 | ||||
2020-02-04 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -9.750 | 39.000 | -20,00 | ||||
2020-02-04 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -12.063 | 24.125 | -33,33 | ||||
2020-02-04 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -14.169 | 1.081.457 | -1,29 | 65,26 | -924.669 | 70.575.884 | |
2020-02-04 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 33.063 | 1.095.626 | 3,11 | ||||
2020-02-04 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
A - Award | 579 | 1.062.563 | 0,05 | 36,68 | 21.238 | 38.974.811 | |
2020-01-23 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -1.031 | 1.061.984 | -0,10 | 82,45 | -85.011 | 87.565.785 |
2020-01-23 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -32.150 | 1.063.015 | -2,94 | 81,85 | -2.631.600 | 87.011.817 |
2020-01-23 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -6.819 | 1.095.165 | -0,62 | 81,01 | -552.436 | 88.723.916 |
2020-01-23 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -523 | 1.101.984 | -0,05 | 83,56 | -43.703 | 92.083.436 |
2020-01-23 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -10.166 | 1.102.507 | -0,91 | 82,78 | -841.562 | 91.267.734 |
2020-01-23 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -29.311 | 1.112.673 | -2,57 | 81,98 | -2.402.837 | 91.213.928 |
2019-12-17 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -87.500 | 0 | -100,00 | ||||
2019-12-17 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -43.383 | 1.141.984 | -3,66 | 76,88 | -3.335.285 | 87.795.730 | |
2019-12-17 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 87.500 | 1.185.367 | 7,97 | ||||
2019-12-09 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -3.716 | 1.097.867 | -0,34 | 76,15 | -282.973 | 83.602.572 |
2019-12-09 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -23.152 | 1.101.583 | -2,06 | 77,72 | -1.799.327 | 85.612.828 |
2019-12-09 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -6.800 | 1.124.735 | -0,60 | 76,78 | -522.122 | 86.360.078 |
2019-12-09 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -6.332 | 1.131.535 | -0,56 | 75,73 | -479.512 | 85.689.222 |
2019-12-09 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -6.750 | 1.137.867 | -0,59 | 75,39 | -508.873 | 85.782.200 |
2019-12-09 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -8.525 | 1.144.617 | -0,74 | 74,66 | -636.478 | 85.457.334 |
2019-12-09 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -996 | 1.153.142 | -0,09 | 74,08 | -73.784 | 85.424.759 |
2019-12-09 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -12.442 | 1.154.138 | -1,07 | 75,35 | -937.475 | 86.961.528 |
2019-12-09 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -11.287 | 1.166.580 | -0,96 | 74,62 | -842.262 | 87.052.883 |
2019-10-02 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 14.812 | 14.812 | |||||
2019-10-02 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Common Stock |
A - Award | 8.294 | 8.294 | |||||
2019-08-05 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -11.250 | 78.750 | -12,50 | ||||
2019-08-05 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -9.750 | 48.750 | -16,67 | ||||
2019-08-05 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -12.062 | 36.188 | -25,00 | ||||
2019-08-05 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -16.394 | 1.177.867 | -1,37 | 54,25 | -889.374 | 63.899.285 | |
2019-08-05 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 33.062 | 1.194.261 | 2,85 | ||||
2019-07-01 |
|
4 | FOLD |
AMICUS THERAPEUTICS, INC.
Stock Options (right to buy) |
A - Award | 19.473 | 19.473 | |||||
2019-07-01 |
|
4 | FOLD |
AMICUS THERAPEUTICS, INC.
Common Stock |
A - Award | 6.250 | 125.145 | 5,26 | ||||
2019-04-10 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -35.000 | 87.500 | -28,57 | ||||
2019-04-10 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -17.354 | 1.161.199 | -1,47 | 58,51 | -1.015.383 | 67.941.753 | |
2019-04-10 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 35.000 | 1.178.553 | 3,06 | ||||
2019-04-10 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
A - Award | 579 | 1.143.553 | 0,05 | 36,68 | 21.238 | 41.945.524 | |
2019-02-05 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -9.750 | 58.500 | -14,29 | ||||
2019-02-05 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -12.063 | 48.250 | -20,00 | ||||
2019-02-05 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
A - Award | 90.000 | 90.000 | |||||
2019-02-05 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 145.000 | 145.000 | |||||
2019-02-05 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -7.814 | 1.142.974 | -0,68 | 48,44 | -378.510 | 55.365.661 | |
2019-02-05 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 21.813 | 1.150.788 | 1,93 | ||||
2018-08-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -9.750 | 68.250 | -12,50 | ||||
2018-08-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -12.062 | 60.313 | -16,67 | ||||
2018-08-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -10.816 | 1.128.975 | -0,95 | 43,15 | -466.710 | 48.715.271 | |
2018-08-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 21.812 | 1.139.791 | 1,95 | ||||
2018-07-17 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Stock Option (Right to Buy) |
M - Exercise | -12.194 | 132.806 | -8,41 | ||||
2018-07-17 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 12.194 | 1.117.979 | 1,10 | 16,40 | 199.982 | 18.334.856 | |
2018-06-11 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Stock Options (right to buy) |
A - Award | 8.912 | 8.912 | |||||
2018-06-11 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
A - Award | 3.081 | 8.895 | 52,99 | ||||
2018-03-13 |
|
4 | CASC |
Cascadian Therapeutics, Inc.
Restricted Stock Units |
D - Sale to Issuer | -13.927 | 0 | -100,00 | ||||
2018-03-13 |
|
4 | CASC |
Cascadian Therapeutics, Inc.
Common Stock |
U - Other | -37.394 | 0 | -100,00 | ||||
2018-02-16 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -35.000 | 122.500 | -22,22 | ||||
2018-02-16 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -17.353 | 1.105.785 | -1,55 | 62,30 | -1.081.092 | 68.890.406 | |
2018-02-16 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 35.000 | 1.123.138 | 3,22 | ||||
2018-02-02 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
A - Award | 78.000 | 78.000 | |||||
2018-02-02 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 122.000 | 122.000 | |||||
2018-02-02 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -12.063 | 72.375 | -14,29 | ||||
2018-02-02 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -5.981 | 1.087.142 | -0,55 | 59,60 | -356.468 | 64.793.663 | |
2018-02-02 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 12.063 | 1.093.123 | 1,12 | ||||
2018-02-02 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -35.000 | 157.500 | -18,18 | ||||
2018-02-02 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -17.353 | 1.081.060 | -1,58 | 57,90 | -1.004.739 | 62.593.374 | |
2018-02-02 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 35.000 | 1.098.413 | 3,29 | ||||
2018-01-26 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -35.000 | 192.500 | -15,38 | ||||
2018-01-26 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -17.354 | 1.063.413 | -1,61 | 58,15 | -1.009.135 | 61.837.466 | |
2018-01-26 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 35.000 | 1.080.767 | 3,35 | ||||
2018-01-18 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -35.000 | 227.500 | -13,33 | ||||
2018-01-18 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -17.083 | 1.045.767 | -1,61 | 52,10 | -890.024 | 54.484.461 | |
2018-01-18 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 35.000 | 1.062.850 | 3,41 | ||||
2017-09-26 |
|
4 | CASC |
Cascadian Therapeutics, Inc.
Restricted Share Unit (RSU) |
M - Exercise | -2.375 | 0 | -100,00 | ||||
2017-09-26 |
|
4 | CASC |
Cascadian Therapeutics, Inc.
Common Stock |
F - Taxes | -594 | 37.394 | -1,56 | 3,94 | -2.340 | 147.332 | |
2017-09-26 |
|
4 | CASC |
Cascadian Therapeutics, Inc.
Common Stock |
M - Exercise | 2.375 | 37.988 | 6,67 | ||||
2017-08-14 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
A - Award | -262.500 | 262.500 | -50,00 | ||||
2017-08-14 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -124.106 | 1.027.850 | -10,77 | 3,40 | -421.340 | 3.489.551 | |
2017-08-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -12.062 | 84.438 | -12,50 | ||||
2017-08-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -4.533 | 1.151.956 | -0,39 | 25,10 | -113.778 | 28.914.096 | |
2017-08-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 12.062 | 1.156.489 | 1,05 | ||||
2017-06-27 |
|
4 | CASC |
Cascadian Therapeutics, Inc.
Restricted Share Unit (RSU) |
M - Exercise | -9.058 | 0 | -100,00 | ||||
2017-06-27 |
|
4 | CASC |
Cascadian Therapeutics, Inc.
Common Stock |
F - Taxes | -2.265 | 35.613 | -5,98 | 3,78 | -8.562 | 134.617 | |
2017-06-27 |
|
4 | CASC |
Cascadian Therapeutics, Inc.
Common Stock |
M - Exercise | 9.058 | 37.878 | 31,43 | ||||
2017-06-16 |
|
4/A | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
A - Award | 5.814 | 147.814 | 4,09 | ||||
2017-06-15 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Stock Options (right to buy) |
A - Award | 16.236 | 16.236 | |||||
2017-06-15 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
A - Award | 5.814 | 5.814 | |||||
2017-06-13 |
|
4 | CASC |
Cascadian Therapeutics, Inc.
Restricted Share Unit (RSU) |
M - Exercise | -2.148 | 0 | -100,00 | ||||
2017-06-13 |
|
4 | CASC |
Cascadian Therapeutics, Inc.
Common Stock |
F - Taxes | -537 | 28.820 | -1,83 | 3,34 | -1.794 | 96.259 | |
2017-06-13 |
|
4 | CASC |
Cascadian Therapeutics, Inc.
Common Stock |
M - Exercise | 2.148 | 29.357 | 7,89 | ||||
2017-06-13 |
|
4 | CASC |
Cascadian Therapeutics, Inc.
Restricted Share Unit (RSU) |
A - Award | 13.927 | 13.927 | |||||
2017-02-14 |
|
5 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
A - Award | 1.413 | 1.144.427 | 0,12 | 13,73 | 19.400 | 15.712.983 | |
2017-02-14 |
|
5 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
A - Award | 378 | 1.143.014 | 0,03 | 15,20 | 5.746 | 17.373.813 | |
2017-02-10 |
|
5 | CASC |
Cascadian Therapeutics, Inc.
Restricted Share Unit (RSU) |
M - Exercise | -2.723 | 0 | -100,00 | ||||
2017-02-10 |
|
5 | CASC |
Cascadian Therapeutics, Inc.
Common Stock |
F - Taxes | -681 | 27.209 | -2,44 | 7,38 | -5.026 | 200.802 | |
2017-02-10 |
|
5 | CASC |
Cascadian Therapeutics, Inc.
Common Stock |
M - Exercise | 2.723 | 27.890 | 10,82 | ||||
2017-02-03 |
|
4 | CASC |
Cascadian Therapeutics, Inc.
Common Stock |
P - Purchase | 23.000 | 27.209 | 546,45 | 4,24 | 97.520 | 115.366 | |
2017-01-19 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 145.000 | 145.000 | |||||
2017-01-19 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
A - Award | 96.500 | 96.500 | |||||
2016-12-16 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -24.821 | 1.139.815 | -2,13 | 3,40 | -84.391 | 3.875.371 | |
2016-06-28 |
|
4 | CASC |
Cascadian Therapeutics, Inc.
Restricted Share Unit (RSU) |
A - Award | 54.347 | 54.347 | |||||
2016-06-13 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Stock Options (right to buy) |
A - Award | 20.000 | 20.000 | |||||
2016-02-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
A - Award | 1.925 | 1.142.636 | 0,17 | 16,09 | 30.973 | 18.385.013 | |
2016-01-07 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
P - Purchase | 2.500 | 2.500 | 20,00 | 50.000 | 50.000 | ||
2016-01-07 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
P - Purchase | 2.500 | 2.500 | 20,00 | 50.000 | 50.000 | ||
2016-01-07 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
P - Purchase | 5.000 | 1.140.711 | 0,44 | 20,00 | 100.000 | 22.814.220 | |
2015-09-28 |
|
4 | ONTY |
Oncothyreon Inc.
Restricted Share Unit (RSU) |
A - Award | 14.245 | 14.245 | |||||
2015-09-09 |
|
4 | ONTY |
Oncothyreon Inc.
Restricted Share Unit (RSU) |
M - Exercise | -17.341 | 0 | -100,00 | ||||
2015-09-09 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
F - Taxes | -4.336 | 13.005 | -25,00 | 3,25 | -14.092 | 42.266 | |
2015-09-09 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
M - Exercise | 17.341 | 17.341 | |||||
2015-08-11 | 3 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
1.157.139 | ||||||||
2015-08-11 | 3 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
1.849.996 | ||||||||
2015-08-11 | 3 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
1.337.139 | ||||||||
2015-08-11 | 3 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
1.234.996 | ||||||||
2015-08-11 | 3 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
1.234.996 | ||||||||
2015-08-11 | 3 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
1.157.139 | ||||||||
2015-08-11 | 3 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
1.849.996 | ||||||||
2015-08-11 | 3 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
1.337.139 | ||||||||
2015-08-11 | 3 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
1.234.996 | ||||||||
2015-08-11 | 3 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
1.234.996 | ||||||||
2015-07-14 |
|
4 | KBIO |
KALOBIOS PHARMACEUTICALS INC
Stock Option (right to buy) |
A - Award | 5.000 | 5.000 | |||||
2015-06-16 |
|
4 | ONTY |
Oncothyreon Inc.
Restricted Share Unit (RSU) |
A - Award | 12.886 | 12.886 | |||||
2015-06-12 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Stock Options (right to buy) |
A - Award | 20.000 | 20.000 | |||||
2014-12-15 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
A - Award | 32.000 | 142.000 | 29,09 | 7,83 | 250.637 | 1.112.201 | |
2014-06-20 |
|
4 | KBIO |
KALOBIOS PHARMACEUTICALS INC
Stock Option (right to buy) |
A - Award | 20.000 | 20.000 | |||||
2014-06-16 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Stock Options (right to buy) |
A - Award | 15.000 | 15.000 | |||||
2014-06-10 |
|
4 | ONTY |
Oncothyreon Inc.
Restricted Share Unit (RSU) |
A - Award | 16.339 | 16.339 | |||||
2014-03-12 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
A - Award | 110.000 | 110.000 | 2,21 | 243.100 | 243.100 | ||
2014-01-06 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
D - Sale to Issuer | -35.000 | 0 | -100,00 | 26,76 | -936.600 | ||
2014-01-06 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
D - Sale to Issuer | -32.500 | 0 | -100,00 | 25,27 | -821.275 | ||
2014-01-06 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
D - Sale to Issuer | -34.500 | 0 | -100,00 | 26,68 | -920.460 | ||
2014-01-06 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
D - Sale to Issuer | -32.000 | 0 | -100,00 | 28,67 | -917.440 | ||
2014-01-06 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
D - Sale to Issuer | -34.500 | 0 | -100,00 | 28,88 | -996.360 | ||
2014-01-06 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
D - Sale to Issuer | -34.500 | 0 | -100,00 | 25,27 | -871.815 | ||
2014-01-06 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
D - Sale to Issuer | -34.500 | 0 | -100,00 | 10,07 | -347.415 | ||
2014-01-06 |
|
4 | SNTS |
SANTARUS INC
Common Stock |
U - Other | -335.500 | 0 | -100,00 | 32,00 | -10.736.000 | ||
2013-09-06 |
|
4 | ONTY |
Oncothyreon Inc.
Restricted Share Unit (RSU) |
A - Award | 17.341 | 17.341 | |||||
2013-09-06 | 3 | ONTY |
Oncothyreon Inc.
Common Stock |
0 | ||||||||
2013-06-21 |
|
4 | MSTX |
Mast Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 62.451 | 62.451 | |||||
2013-06-17 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Stock Options (right to buy) |
A - Award | 15.000 | 15.000 | |||||
2013-06-12 |
|
4 | SNTS |
SANTARUS INC
Stock Option (right to buy) |
A - Award | 34.500 | 34.500 | |||||
2013-05-02 |
|
4 | KBIO |
KALOBIOS PHARMACEUTICALS INC
Stock Option (right to buy) |
A - Award | 15.000 | 15.000 | |||||
2012-12-19 |
|
4 | SNTS |
SANTARUS INC
Common Stock |
P - Purchase | 185.000 | 335.500 | 122,92 | 10,88 | 2.012.800 | 3.650.240 | |
2012-09-07 |
|
4 | ANX |
ADVENTRX PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 14.171 | 14.171 | |||||
2012-09-07 |
|
4 | ANX |
ADVENTRX PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 18.895 | 18.895 | |||||
2012-07-27 |
|
4 | ONXX |
ONYX PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -5.241 | 77.756 | -6,31 | 73,97 | -387.687 | 5.751.759 |
2012-06-18 |
|
4 | AFFY |
AFFYMAX INC
Stock Option (Right to Buy) |
A - Award | 12.000 | 12.000 | |||||
2012-06-15 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Stock Option (right to buy) |
A - Award | 30.000 | 30.000 | |||||
2012-06-14 |
|
4 | SNTS |
SANTARUS INC
Stock Option (right to buy) |
A - Award | 34.500 | 34.500 | |||||
2012-04-03 |
|
4 | ONXX |
ONYX PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | X | -757 | 82.997 | -0,90 | 36,58 | -27.689 | 3.035.831 |
2012-04-03 |
|
4 | ONXX |
ONYX PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 49.700 | 49.700 | |||||
2012-04-03 |
|
4 | ONXX |
ONYX PHARMACEUTICALS INC
Common Stock |
A - Award | 17.150 | 83.754 | 25,75 | ||||
2012-04-03 |
|
4 | ONXX |
ONYX PHARMACEUTICALS INC
Common Stock |
A - Award | 9.800 | 66.604 | 17,25 | ||||
2012-03-12 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
M - Exercise | -34.500 | 0 | -100,00 | ||||
2012-03-12 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
M - Exercise | -34.500 | 0 | -100,00 | ||||
2012-03-12 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
M - Exercise | -34.500 | 0 | -100,00 | ||||
2012-03-12 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
M - Exercise | -32.000 | 0 | -100,00 | ||||
2012-03-12 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
M - Exercise | -15.000 | 0 | -100,00 | ||||
2012-03-12 |
|
4 | SNTS |
SANTARUS INC
Common Stock |
M - Exercise | 34.500 | 150.500 | 29,74 | 2,47 | 85.215 | 371.735 | |
2012-03-12 |
|
4 | SNTS |
SANTARUS INC
Common Stock |
M - Exercise | 34.500 | 116.000 | 42,33 | 2,38 | 82.110 | 276.080 | |
2012-03-12 |
|
4 | SNTS |
SANTARUS INC
Common Stock |
M - Exercise | 32.000 | 81.500 | 64,65 | 1,18 | 37.760 | 96.170 | |
2012-03-12 |
|
4 | SNTS |
SANTARUS INC
Common Stock |
M - Exercise | 34.500 | 49.500 | 230,00 | 2,02 | 69.690 | 99.990 | |
2012-03-12 |
|
4 | SNTS |
SANTARUS INC
Common Stock |
M - Exercise | 15.000 | 15.000 | 3,00 | 45.000 | 45.000 | ||
2012-02-03 |
|
4 | ONXX |
ONYX PHARMACEUTICALS INC
Common Stock |
F - Taxes | -2.098 | 56.804 | -3,56 | 41,98 | -88.074 | 2.384.632 | |
2009-03-03 |
|
4 | ABIO |
ARCA biopharma, Inc.
Option to Purchase Common Stock |
A - Award | 7.500 | 7.500 |